Ring Therapeutics has entered into new strategic partnerships with the Agency for Science, Technology, and Research (A*STAR) and the Singapore Eye Research Institute (SERI) to enhance research and development (R&D) efforts in the biomedical sciences sector.
Amgen has announced the receipt of approval from the Japan’s Ministry of Health, Labour and Welfare (MHLW) for TEPEZZA (Teprotumumab) to treat active or high clinical activity score (CAS) thyroid eye disease (TED).
Skyline Therapeutics has announced that the US Food and Drug Administration (FDA) granted orphan drug designation (ODD) to its gene therapy, SKG1108, for the treatment of Retinitis Pigmentosa (RP), an inherited retinal disease.
The US Food and Drug Administration (FDA) has granted approval for Sandoz's Enzeevu (aflibercept-abzv) 2mg vial kit and pre-filled syringe for intravitreal injection, a biosimilar aimed at treating neovascular age-related macular degeneration (nAMD).
MSD (Merck & Co) has completed the acquisition of EyeBio, making it a wholly-owned subsidiary, and bolstering its ophthalmology portfolio.
Beacon Therapeutics has announced a successful $170m Series B funding round, led by Forbion, to accelerate the development of its ophthalmic gene therapies, including its lead asset AGTC-501.
The US Food and Drug Administration (FDA) has granted approval to Formosa Pharmaceuticals and AimMax Therapeutics’ clobetasol propionate ophthalmic suspension 0.05% for post-operative inflammation and pain after ocular surgical procedure.
Entos Pharmaceuticals has inaugurated a new Good Manufacturing Practices (GMP) manufacturing facility in Carlsbad, California in the US.
BlueRock Therapeutics has exercised its exclusive option to license induced pluripotent stem cell (iPSC)-derived cell therapy candidate from FUJIFILM Cellular Dynamics and Opsis Therapeutics.
Novartis has concluded the sale of its ‘front of eye’ ophthalmology assets to eye health company Bausch + Lomb for up to $2.5bn.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.